The Effects of 23-Gauge Pars Plana Vitrectomy on Orbital Circulation Using Doppler Ultrasonography in Diabetic Macular Edema with Epiretinal Membrane and Taut Posterior Hyaloid

Güngel, Hülya; Altan, Çiğdem; Baylancicek, Deniz Oygar; Karagöz, Yeşim; Kisbet, Tanju

doi:10.3109/02713683.2016.1150492

Cited by 6 publications

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The treatment for DME mainly includes laser photocoagulation, glucocorticoid or anti-vascular endothelial growth factor (VEGF) drug intravitreal injection therapy and vitreous surgery [3][4][5]. However, pan-retinal photocoagulation (PRP) can result in limited peripheral vision, decreased night version and aggravated DME [6].…”

Section: Introductionmentioning

confidence: 99%

Ranibizumab Pretreatment in Vitrectomy with Internal Limiting Membrane Peeling on Diabetic Macular Edema in Severe Proliferative Diabetic Retinopathy

et al. 2020

View full text Add to dashboard Cite

Aim: To evaluate the efficacy of intravitreal ranibizumab (IVR) pretreatment for pars plana vitrectomy (PPV) with internal limiting membrane (ILM) peeling in severe proliferative diabetic retinopathy (PDR) combined with macular edema (ME). Methods: Sixty-three patients with ME and PDR were divided into IVR and control groups. Three days before PPV stripping, ranibizumab was injected into the patients in the IVR group. The patients were followed for 6 months. The bestcorrected visual acuity (BCVA), visual acuity improvement, centre macular thickness (CMT), and intraoperative and postoperative complications were compared between the two groups. Results: The BCVA of the IVR group was significantly improved at 1, 3 and 6 months compared with the preoperative BCVA (P \ 0.01). The BCVA of the control group was significantly improved at 3 and 6 months compared with the preoperative BCVA (P \ 0.01), but was not significantly improved at 1 month. At 1 and 3 months, the BCVA of the IVR group was significantly better than that of the control group after surgery, with no difference between the two groups at 6 months. The CMT of the IVR group was thinner than that of the control group at 1 and 3 months (P \ 0.01), with no significant difference at 6 months after surgery. The surgical time, the risk of intraoperative bleeding, the incidence of iatrogenic retinal breaks, the frequency of endodiathermy and the rate of silicone oil tamponade were significantly different between the two groups (all P \ 0.05). There was no significant difference between the two groups in terms of postoperative complications. Conclusions: Ranibizumab pretreatment may improve the outcome of PPV with ILM peeling for severe PDR with ME by decreasing ME and intraoperative complications.

show abstract

Section: Introductionmentioning

confidence: 99%